216 related articles for article (PubMed ID: 34188177)
1. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Yao JY; Xu S; Sun YN; Xu Y; Guo QL; Wei LB
Acta Pharmacol Sin; 2022 Apr; 43(4):1033-1045. PubMed ID: 34188177
[TBL] [Abstract][Full Text] [Related]
2. CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma.
Yao J; Wang J; Xu Y; Guo Q; Sun Y; Liu J; Li S; Guo Y; Wei L
Autophagy; 2022 Aug; 18(8):1879-1897. PubMed ID: 34890308
[TBL] [Abstract][Full Text] [Related]
3. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
4. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
5. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Shao YY; Hsu HW; Wo RR; Wang HY; Cheng AL; Hsu CH
Oncology; 2022; 100(11):602-611. PubMed ID: 36103810
[TBL] [Abstract][Full Text] [Related]
7. CDK9 inhibitors reactivate p53 by downregulating iASPP.
Wu J; Liang Y; Tan Y; Tang Y; Song H; Wang Z; Li Y; Lu M
Cell Signal; 2020 Mar; 67():109508. PubMed ID: 31866490
[TBL] [Abstract][Full Text] [Related]
8. MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development.
Xie X; Wang X; Liao W; Fei R; Wu N; Cong X; Chen Q; Wei L; Wang Y; Chen H
J Exp Clin Cancer Res; 2018 Feb; 37(1):28. PubMed ID: 29439719
[TBL] [Abstract][Full Text] [Related]
9. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Zhang MF; Zhang ZY; Fu J; Yang YF; Yun JP
J Transl Med; 2009 Dec; 7():110. PubMed ID: 20025780
[TBL] [Abstract][Full Text] [Related]
10. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
11. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
[TBL] [Abstract][Full Text] [Related]
12. Cdk9 phosphorylates Pirh2 protein and prevents degradation of p53 protein.
Bagashev A; Fan S; Mukerjee R; Claudio PP; Chabrashvili T; Leng RP; Benchimol S; Sawaya BE
Cell Cycle; 2013 May; 12(10):1569-77. PubMed ID: 23603988
[TBL] [Abstract][Full Text] [Related]
13. Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.
Dai Q; Yin Y; Liu W; Wei L; Zhou Y; Li Z; You Q; Lu N; Guo Q
Int J Biochem Cell Biol; 2013 Jul; 45(7):1468-78. PubMed ID: 23612020
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p53 in oroxylin A-induced apoptosis in cancer cells.
Mu R; Qi Q; Gu H; Wang J; Yang Y; Rong J; Liu W; Lu N; You Q; Guo Q
Mol Carcinog; 2009 Dec; 48(12):1159-69. PubMed ID: 19626645
[TBL] [Abstract][Full Text] [Related]
16. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
18. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
19. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
20. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
